MX2017007245A - Metodos de tratamiento de la fibrosis. - Google Patents

Metodos de tratamiento de la fibrosis.

Info

Publication number
MX2017007245A
MX2017007245A MX2017007245A MX2017007245A MX2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A MX 2017007245 A MX2017007245 A MX 2017007245A
Authority
MX
Mexico
Prior art keywords
methods
treating fibrosis
patient
inhibitor
btk inhibitor
Prior art date
Application number
MX2017007245A
Other languages
English (en)
Inventor
Soucek Laura
Jauset Gonzalez Toni
Masso-Valles Daniel
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017007245A publication Critical patent/MX2017007245A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B31/00Disazo and polyazo dyes of the type A->B->C, A->B->C->D, or the like, prepared by diazotising and coupling
    • C09B31/02Disazo dyes
    • C09B31/12Disazo dyes from other coupling components "C"
    • C09B31/14Heterocyclic components
    • C09B31/1431,2-Diazoles
    • C09B31/147Pyrazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para el tratamiento de la fibrosis en un paciente, que comprenden administrarle a un paciente que lo necesite una cantidad terapéuticamente eficaz de un inhibidor de ACK (por ejemplo, un inhibidor de BTK, tal como, por ejemplo, un inhibidor de BTK irreversible, tal como, por ejemplo, ibrutinib).
MX2017007245A 2014-12-03 2015-12-02 Metodos de tratamiento de la fibrosis. MX2017007245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086945P 2014-12-03 2014-12-03
PCT/US2015/063475 WO2016090021A1 (en) 2014-12-03 2015-12-02 Methods of treating fibrosis

Publications (1)

Publication Number Publication Date
MX2017007245A true MX2017007245A (es) 2018-02-16

Family

ID=56092404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007245A MX2017007245A (es) 2014-12-03 2015-12-02 Metodos de tratamiento de la fibrosis.

Country Status (12)

Country Link
US (2) US9844552B2 (es)
EP (1) EP3226864A4 (es)
JP (1) JP2017536397A (es)
CN (1) CN106999482A (es)
AR (1) AR102871A1 (es)
AU (1) AU2015358503A1 (es)
BR (1) BR112017011897A2 (es)
CA (1) CA2968866A1 (es)
HK (1) HK1244692A1 (es)
MX (1) MX2017007245A (es)
TW (2) TW201740953A (es)
WO (1) WO2016090021A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928721C (en) 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es) * 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CN113694187A (zh) * 2021-07-20 2021-11-26 上海市东方医院(同济大学附属东方医院) 一种用于抑制心肌纤维化的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279794B2 (en) * 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
WO2011133609A2 (en) * 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
CA2928721C (en) 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
WO2015084857A1 (en) 2013-12-02 2015-06-11 Pharmacyclics, Inc. Methods of treating and preventing alloantibody driven chronic graft versus host disease
RU2646758C2 (ru) 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
US9982265B2 (en) 2014-03-28 2018-05-29 Board Of Regents, The University Of Texas System Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis

Also Published As

Publication number Publication date
US20160199376A1 (en) 2016-07-14
BR112017011897A2 (pt) 2018-07-03
HK1244692A1 (zh) 2018-08-17
EP3226864A1 (en) 2017-10-11
TW201625257A (zh) 2016-07-16
AU2015358503A1 (en) 2017-06-08
CN106999482A (zh) 2017-08-01
WO2016090021A1 (en) 2016-06-09
US10226466B2 (en) 2019-03-12
US9844552B2 (en) 2017-12-19
EP3226864A4 (en) 2018-04-04
AR102871A1 (es) 2017-03-29
US20180153896A1 (en) 2018-06-07
CA2968866A1 (en) 2016-06-09
JP2017536397A (ja) 2017-12-07
TW201740953A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12015502075B1 (en) Treatment of cataplexy
NZ730809A (en) Methods for treating filoviridae virus infections
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
GB2541571A (en) Pharmaceutical compositions
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201692534A1 (ru) Способы лечения гипотонии
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
IN2014MU00916A (es)
PH12014502065A1 (en) Vesicular formulations
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
EA201690446A1 (ru) Лечение множественной миеломы
MX2018011379A (es) Tratamiento del prurito uremico.
MX2016002307A (es) Tratamiento para el cancer.
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
WO2015187733A3 (en) Myostatin inhibitors for treatment of diabetes
IN2014DE00822A (es)